Gavin Canzanese

[1] Semaglutide drugs, sold under the brand names Ozempic and Wegovy, saw a substantial increase in use for treating diabetes and obesity, driving nationwide shortages. [2]  During the shortage, the FDA’s drug-shortage-list policies allowed compounding to expand as a practical substitute for the approved products.  [3]   Background Pharmacies compound patient-specific drugs when a suitable commercial product is unavailable. [4]  Under § 503A of the Food, Drug, and Cosmetic Act (“FDCA”),...

Photograph of the U.S. Capital Building [1] On December 8th of 2023, controversy struck when the National Institute of Standards and...